Neogen Chemicals Q1 FY27 Revenue Jumps 34% to ₹250 Crore, PAT Surges 67%
Neogen Chemicals reported a 34% YoY revenue growth to ₹250.3 crore and a 67% PAT surge to ₹17.1 crore for Q1 FY27. Consolidated EBITDA increased by 53% to ₹48.2 crore. The company's board approved raising ₹600 crore via QIP for expansion. Battery materials projects are on track.
The significant increase in revenue and profit, coupled with the approval for a substantial fundraise (QIP) for expansion and positive updates on key projects like battery materials, indicates a high impact on the company's future growth and financial performance.
The company reported strong year-on-year growth in revenue and profit, along with positive updates on plant reconstruction and expansion projects, indicating a positive outlook.
Neogen Chemicals Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting a significant increase in both revenue and profit. Consolidated revenue grew by 34% year-on-year to ₹250.3 crore, up from ₹186.7 crore in Q1 FY26. Profit After Tax (PAT) on a consolidated basis surged by 67% to ₹17.1 crore, compared to ₹10.3 crore in the same period last year.
Standalone revenue also saw robust growth, increasing by 37% to ₹252.3 crore from ₹184.6 crore in Q1 FY26. Standalone PAT rose by 37% to ₹19.4 crore from ₹14.2 crore. The company's EBITDA on a consolidated basis increased by 53% to ₹48.2 crore, with EBITDA margins improving by 260 basis points to 19.3%. Standalone EBITDA also grew by 39% to ₹48.2 crore, with margins improving by 30 basis points to 19.1%.
The company highlighted that despite temporary plant shutdowns and global headwinds, revenue expansion was driven by higher volumes in key product lines, particularly the Organolithium portfolio. Neogen Ionics (NIL), a subsidiary, contributed ₹19 crore in revenue in Q1 FY27, a substantial increase from ₹5 crore in Q1 FY26.
Neogen Chemicals also provided an update on the reconstruction of its Dahej plant, which is complete with trial runs underway and commercial production expected soon. The company's board has approved raising up to ₹600 crore through a Qualified Institutional Placement (QIP) to fund its expansion initiatives. The battery materials projects, including Electrolyte and Electrolyte Salts, are on schedule for commissioning in H1 FY27 and H2 FY27, respectively. The total estimated project cost for Neogen Ionics' Dahej Phase 1 and Pakhajan Phase 2 Battery Materials projects is ₹1,795 crore.
Dr. Harin Kanani, Managing Director, expressed optimism, stating that FY27 will be a defining year for Neogen Chemicals, with the commissioning and scaling up of its battery materials project and the resumption of its base business's normalized growth trajectory. The company reaffirmed its guidance and focus on executing its strategic CAPEX roadmap.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.